IPSOGEN history

IPSOGEN was founded in 1999 in Marseille, France, by Vincent FERT, Stéphane DEBONO and Fabienne HERMITTE. All three cofounders are still involved in the executive managment and the development of the company.

IPSOGEN was created with the support of Bertrand Jordan (Director of research CNRS) and Daniel Birnbaum (Director of research Inserm) and also took advantages of its historical partnership with Institut Paoli-Calmettes, Cancer Research Center, Marseille, where both scientific teams collaboration benefits from the close relationship.

A solid growth since inception

 
2011: IPSOGEN becomes a subsidiary of the QIAGEN group.
The BCR‐ABL IS‐MMR kit by IPSOGEN, ensuring inter–laboratory testing harmonization in the measurement of BCR‐ABL transcripts, is a success through worldwide molecular laboratories. Sales 9.50M€

2010: First clinical use of Genomic Grade. Sales 8.37M€

2009: Genomic Grade in the St Gallen guidance’s. Sales 6,7M€

2008: Listing on the Alternext market (Alips).
JAK2 mutation test recommended by the World Health Organisation (WHO). IPSOGEN patent on JAK2 V617F extended to the US. Sales 4,2M€

2007: License agreement with ULB for the Genomic Grade test, a breast cancer biomarker

2006: License agreement with Institut Gustave Roussy and several other French Institutions for the JAK2 V617F mutation, a leukemia biomarker

2005: Foundation of our US subsidiary: IPSOGEN Inc., Connecticut, USA

2004: License agreement for WT1, a leukemia biomarker

2003: License agreement for a portfolio of technologies dedicated to measuring leukemia biomarkers

2001: First round of financing – 5 M€

1999: Company inception